NO20032531D0 - Tetralon-derivater som antitumormidler - Google Patents
Tetralon-derivater som antitumormidlerInfo
- Publication number
- NO20032531D0 NO20032531D0 NO20032531A NO20032531A NO20032531D0 NO 20032531 D0 NO20032531 D0 NO 20032531D0 NO 20032531 A NO20032531 A NO 20032531A NO 20032531 A NO20032531 A NO 20032531A NO 20032531 D0 NO20032531 D0 NO 20032531D0
- Authority
- NO
- Norway
- Prior art keywords
- antitumor agents
- tetralone derivatives
- tetralone
- derivatives
- antitumor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D295/116—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings with the doubly bound oxygen or sulfur atoms directly attached to a carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
- C07D213/50—Ketonic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP00126820 | 2000-12-07 | ||
| PCT/EP2001/014311 WO2002046144A1 (en) | 2000-12-07 | 2001-12-06 | Tetralone derivatives as antitumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20032531L NO20032531L (no) | 2003-06-04 |
| NO20032531D0 true NO20032531D0 (no) | 2003-06-04 |
Family
ID=8170594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20032531A NO20032531D0 (no) | 2000-12-07 | 2003-06-04 | Tetralon-derivater som antitumormidler |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6531472B2 (hu) |
| EP (1) | EP1349830A1 (hu) |
| JP (1) | JP4091431B2 (hu) |
| KR (1) | KR20030077551A (hu) |
| CN (1) | CN100340545C (hu) |
| AR (1) | AR035659A1 (hu) |
| AU (2) | AU2002216074C1 (hu) |
| BG (1) | BG107889A (hu) |
| BR (1) | BR0115988A (hu) |
| CA (1) | CA2430355A1 (hu) |
| CZ (1) | CZ20031833A3 (hu) |
| EC (1) | ECSP034642A (hu) |
| HK (1) | HK1060875A1 (hu) |
| HR (1) | HRP20030451A2 (hu) |
| HU (1) | HUP0400579A2 (hu) |
| IL (1) | IL156133A0 (hu) |
| MA (1) | MA26972A1 (hu) |
| MX (1) | MXPA03004947A (hu) |
| NO (1) | NO20032531D0 (hu) |
| NZ (1) | NZ526051A (hu) |
| PL (1) | PL365324A1 (hu) |
| RU (1) | RU2288220C2 (hu) |
| SK (1) | SK8512003A3 (hu) |
| WO (1) | WO2002046144A1 (hu) |
| YU (1) | YU45803A (hu) |
| ZA (1) | ZA200304262B (hu) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6822267B1 (en) * | 1997-08-20 | 2004-11-23 | Advantest Corporation | Signal transmission circuit, CMOS semiconductor device, and circuit board |
| US6706686B2 (en) * | 2001-09-27 | 2004-03-16 | The Regents Of The University Of Colorado | Inhibition of histone deacetylase as a treatment for cardiac hypertrophy |
| WO2003032921A2 (en) * | 2001-10-16 | 2003-04-24 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases and cancer of the brain |
| US7148257B2 (en) | 2002-03-04 | 2006-12-12 | Merck Hdac Research, Llc | Methods of treating mesothelioma with suberoylanilide hydroxamic acid |
| ES2532607T3 (es) | 2002-03-04 | 2015-03-30 | Merck Hdac Research, Llc | Métodos de inducción de la diferenciación terminal |
| US7456219B2 (en) | 2002-03-04 | 2008-11-25 | Merck Hdac Research, Llc | Polymorphs of suberoylanilide hydroxamic acid |
| AU2003226014A1 (en) * | 2002-03-28 | 2003-10-13 | Brigham And Women's Hospital, Inc. | Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
| AU2003219555A1 (en) * | 2002-04-05 | 2003-10-20 | Fujisawa Pharmaceutical Co., Ltd. | Depsipeptide for therapy of kidney cancer |
| CN100566711C (zh) * | 2002-04-15 | 2009-12-09 | 斯隆-凯特林癌症研究院 | 治疗癌症的化合物及其用途 |
| GB0217777D0 (en) * | 2002-07-31 | 2002-09-11 | Novartis Ag | Organic compounds |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1570061A2 (en) * | 2002-12-05 | 2005-09-07 | Imperial College Innovations Limited | Control of apoptosis using a complex of an oligonucleotide and a regulatory peptide |
| KR20050122210A (ko) | 2003-03-17 | 2005-12-28 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| DE602004026321D1 (de) | 2003-08-26 | 2010-05-12 | Merck Hdac Res Llc | Verwendung von SAHA zur Behandlung von Mesotheliom |
| EP1667680A4 (en) | 2003-08-29 | 2008-10-08 | Aton Pharma Inc | COMBINED METHODS OF TREATING CANCER |
| WO2005066151A2 (en) * | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20050159470A1 (en) * | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
| CA2561954A1 (en) * | 2004-04-05 | 2005-10-20 | Myogen, Inc. | Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure |
| WO2005099747A1 (en) * | 2004-04-14 | 2005-10-27 | Medical Research Council | Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6 |
| KR100632800B1 (ko) | 2004-10-21 | 2006-10-16 | 한국화학연구원 | 히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법 |
| US7642275B2 (en) * | 2004-12-16 | 2010-01-05 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1896436A2 (en) * | 2005-05-11 | 2008-03-12 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| TWI365068B (en) | 2005-05-20 | 2012-06-01 | Merck Sharp & Dohme | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
| CN101263121A (zh) * | 2005-07-14 | 2008-09-10 | 塔克达圣地亚哥公司 | 组蛋白脱乙酰基酶抑制剂 |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| EP1976835A2 (en) * | 2006-01-13 | 2008-10-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20100137239A1 (en) | 2006-04-24 | 2010-06-03 | Gloucester Pharmaceuticals | Gemcitabine combination therapy |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2015051035A1 (en) | 2013-10-01 | 2015-04-09 | The J. David Gladstone Institutes | Compositions, systems and methods for gene expression noise drug screening and uses thereof |
| EP3769757A3 (en) * | 2013-10-18 | 2021-10-06 | The General Hospital Corporation | Imaging histone deacetylases with a radiotracer using positron emission tomography |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| EP3461488A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dbait molecule and a hdac inhibitor for treating cancer |
| TWI799691B (zh) * | 2019-03-29 | 2023-04-21 | 景凱生物科技股份有限公司 | 具有側鏈烷基與烯基延伸的苯基衍生物及包括有其的藥學組合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023041805A1 (en) | 2021-09-20 | 2023-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for improving the efficacy of hdac inhibitor therapy and predicting the response to treatment with hdac inhibitor |
| WO2023194441A1 (en) | 2022-04-05 | 2023-10-12 | Istituto Nazionale Tumori Irccs - Fondazione G. Pascale | Combination of hdac inhibitors and statins for use in the treatment of pancreatic cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4448730A (en) * | 1981-03-24 | 1984-05-15 | Riet Bartholomeus Van T | Hydroxybenzohydroxamic acids, benzamides and esters and related compounds as ribonucleotide reductase inhibitors |
| JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5637946A (en) * | 1993-10-28 | 1997-06-10 | Lockheed Corporation | Thermally energized electrical power source |
| AUPO721997A0 (en) | 1997-06-06 | 1997-07-03 | Queensland Institute Of Medical Research, The | Anticancer compounds |
-
2001
- 2001-11-27 AR ARP010105504A patent/AR035659A1/es not_active Application Discontinuation
- 2001-12-04 US US10/006,173 patent/US6531472B2/en not_active Expired - Fee Related
- 2001-12-06 IL IL15613301A patent/IL156133A0/xx unknown
- 2001-12-06 PL PL01365324A patent/PL365324A1/xx not_active Application Discontinuation
- 2001-12-06 SK SK851-2003A patent/SK8512003A3/sk unknown
- 2001-12-06 WO PCT/EP2001/014311 patent/WO2002046144A1/en active IP Right Grant
- 2001-12-06 CN CNB018197345A patent/CN100340545C/zh not_active Expired - Fee Related
- 2001-12-06 HU HU0400579A patent/HUP0400579A2/hu unknown
- 2001-12-06 CZ CZ20031833A patent/CZ20031833A3/cs unknown
- 2001-12-06 MX MXPA03004947A patent/MXPA03004947A/es active IP Right Grant
- 2001-12-06 YU YU45803A patent/YU45803A/sh unknown
- 2001-12-06 NZ NZ526051A patent/NZ526051A/xx unknown
- 2001-12-06 JP JP2002547883A patent/JP4091431B2/ja not_active Expired - Fee Related
- 2001-12-06 BR BR0115988-7A patent/BR0115988A/pt not_active IP Right Cessation
- 2001-12-06 AU AU2002216074A patent/AU2002216074C1/en not_active Ceased
- 2001-12-06 RU RU2003119658/04A patent/RU2288220C2/ru active
- 2001-12-06 KR KR10-2003-7007640A patent/KR20030077551A/ko not_active Application Discontinuation
- 2001-12-06 CA CA002430355A patent/CA2430355A1/en not_active Abandoned
- 2001-12-06 EP EP01999552A patent/EP1349830A1/en not_active Withdrawn
- 2001-12-06 AU AU1607402A patent/AU1607402A/xx active Pending
-
2003
- 2003-05-30 ZA ZA200304262A patent/ZA200304262B/en unknown
- 2003-06-04 MA MA27193A patent/MA26972A1/fr unknown
- 2003-06-04 HR HR20030451A patent/HRP20030451A2/hr not_active Application Discontinuation
- 2003-06-04 NO NO20032531A patent/NO20032531D0/no not_active Application Discontinuation
- 2003-06-05 EC EC2003004642A patent/ECSP034642A/es unknown
- 2003-06-06 BG BG107889A patent/BG107889A/bg unknown
-
2004
- 2004-06-01 HK HK04103910A patent/HK1060875A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0115988A (pt) | 2004-01-13 |
| BG107889A (bg) | 2004-06-30 |
| AU2002216074B2 (en) | 2006-01-05 |
| AR035659A1 (es) | 2004-06-23 |
| PL365324A1 (en) | 2004-12-27 |
| CN1478072A (zh) | 2004-02-25 |
| RU2288220C2 (ru) | 2006-11-27 |
| MXPA03004947A (es) | 2003-09-10 |
| MA26972A1 (fr) | 2004-12-20 |
| JP4091431B2 (ja) | 2008-05-28 |
| US20020065282A1 (en) | 2002-05-30 |
| US6531472B2 (en) | 2003-03-11 |
| AU2002216074C1 (en) | 2006-12-07 |
| IL156133A0 (en) | 2003-12-23 |
| NO20032531L (no) | 2003-06-04 |
| NZ526051A (en) | 2004-12-24 |
| HRP20030451A2 (en) | 2005-04-30 |
| WO2002046144A1 (en) | 2002-06-13 |
| ECSP034642A (es) | 2003-07-25 |
| SK8512003A3 (en) | 2004-04-06 |
| JP2004515488A (ja) | 2004-05-27 |
| HK1060875A1 (en) | 2004-08-27 |
| CA2430355A1 (en) | 2002-06-13 |
| HUP0400579A2 (hu) | 2004-06-28 |
| EP1349830A1 (en) | 2003-10-08 |
| CN100340545C (zh) | 2007-10-03 |
| YU45803A (sh) | 2006-05-25 |
| CZ20031833A3 (cs) | 2004-02-18 |
| ZA200304262B (en) | 2004-08-30 |
| AU1607402A (en) | 2002-06-18 |
| KR20030077551A (ko) | 2003-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20032531D0 (no) | Tetralon-derivater som antitumormidler | |
| NO20026195D0 (no) | Substituerte-triazolopyrimidiner som anticancer midler | |
| NO20042955L (no) | Substituerte fenylaftalener som estrogene midler | |
| NO20042279L (no) | Kinazolinderivater som antitumormidler | |
| NO20042288L (no) | Kinazolinderivater som antitumormidler | |
| NO20015477L (no) | 4,5,6,7-tetrahydroindazolderivater som antitumormidler | |
| DK1414440T3 (da) | N-phenylpyrrolguanidinderivater som melanocortinreceptorligander | |
| NO20013671L (no) | Substituerte bisycliske derivater nyttige som anticancer midler | |
| DK1292604T3 (da) | 2-Aminocarbonyl-9H-purinderivater | |
| DK1326858T3 (da) | Piperidinforbindelser som anti-allergiske midler | |
| ATE319451T1 (de) | Tetrahydrochinolin-derivate | |
| ATE312827T1 (de) | 3-substituierte-4-pyrimidonderivate | |
| ATE288437T1 (de) | Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e | |
| DK1456206T3 (da) | Azaindolylalkylaminderivater som 5-hydroxytryptamin-6-ligander | |
| ATE298332T1 (de) | Decahydro-isochinolinderivate | |
| DK1280809T3 (da) | Antitumorecteinascidinderivater | |
| DK1455779T3 (da) | Indolylalkylaminderivater som 5-hydroxytryptamin-6-ligander | |
| DK1322654T3 (da) | Platinkomplekser som antitumormidler | |
| NO20034647L (no) | Hydroksyclylalkoksy-, alkyloksy- og -alkylaminobenzazol- derivater som 5-hydroksytryptamin-6-ligander | |
| ATE334114T1 (de) | Substituierte c-cyclohexylmethylamin-derivate | |
| DE60223031D1 (de) | Arylpiperazin gebundene tetrahydroindolonderivate | |
| DK1263734T3 (da) | 3-thiomethylpyrazoler som pesticider | |
| DK1322593T3 (da) | O-substituerede-6-methyl-tramadol-derivater | |
| PT1351959E (pt) | Novos derivados de pleuromutilina | |
| ATE282021T1 (de) | Substituierte aminomethyl-phenyl- cyclohexanderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |